US Executive Compensation Proxy SEC Filings — July 20, 2026

20-07-2026

FutureTech II Acquisition Corp. filed a DEF 14A proxy statement seeking stockholder approval for an extension to complete a business combination, with significant risks including potential CFIUS scrutiny due to prior non-U.S. sponsor ties, OTC Markets listing leading to penny stock classification, and possible Investment Company Act implications. The sponsor owns 82.8% of outstanding shares and faces a conflict of interest as its entire investment would be lost if no deal closes. While the company has a merger agreement with Longevity Biomedical Inc., the OTC listing may hinder meeting Nasdaq listing requirements for the combined entity, and redemptions could leave insufficient cash to close the deal.

• · The company's securities are traded on OTC Markets, not Nasdaq, which may affect ability to close the Longevity Biomedical merger as Nasdaq listing is a condition precedent.
• · To mitigate Investment Company Act risk, the trustee has been instructed to liquidate U.S. government treasury obligations and hold funds in an interest-bearing bank demand deposit account.
• · Sponsor and directors/officers have waived rights to liquidating distributions from the Trust Account with respect to Founder Shares.
• · The company may be subject to CFIUS review if the target is a U.S. company in a regulated industry or affecting national security.
• · Penny stock rules could reduce secondary market trading activity and liquidity for the company's common stock.

20-07-2026

ElectroCore, Inc. filed its DEF 14A proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on September 8, 2026. The meeting will include the election of three Class II directors, ratification of CBIZ CPAs as independent auditors for FY2026, and a non-binding advisory vote on named executive officer compensation. The record date is July 10, 2026, with 9,015,885 shares outstanding.

• · Annual Meeting will be held virtually on September 8, 2026 at 9:00 a.m. Eastern Time.
• · Proposal 1: Election of three Class II directors (Thomas J. Errico, M.D., James C. Theofilos, Elena Bonfiglioli) for terms expiring at the 2029 annual meeting.
• · Proposal 2: Ratification of CBIZ CPAs P.C. as independent auditors for fiscal year ending December 31, 2026.
• · Proposal 3: Non-binding advisory vote on named executive officer compensation (Say on Pay).
• · Record date: July 10, 2026.
• · Board recommends voting FOR all proposals.

20-07-2026

Origin Materials, Inc. is seeking stockholder approval to dissolve and liquidate the company under an Amended and Restated Plan of Complete Liquidation and Dissolution. The Board of Directors unanimously recommends the dissolution after concluding that continuing as a going concern or pursuing a strategic transaction is unlikely to create greater value for stockholders. The special meeting is scheduled for August 12, 2026, and the company intends to distribute available proceeds to stockholders as quickly as possible.

• · The Board of Directors unanimously approved the dissolution on May 1, 2026.
• · The record date for the special meeting is July 8, 2026.
• · The company will close its stock transfer books on the Final Record Date, after which shares will not be transferable except by will, intestate succession, or operation of law.
• · The Board retains discretion to abandon or delay dissolution before filing the Certificate of Dissolution if circumstances change.
• · A contingency reserve may be set aside to satisfy claims and contingent obligations.

20-07-2026

Inflection Point Acquisition Corp. V (IPEXU) filed a definitive proxy statement (DEF 14A) on July 20, 2026, seeking shareholder approval to extend the deadline for its initial business combination with GOWell Technology Limited from August 14, 2026 to December 31, 2026 (via a one-month extension to August 31, 2026, with up to four additional one-month extensions). The extension is needed because the parties are still working on SEC filings and other conditions for the business combination. Shareholders who do not wish to wait may redeem their Public Shares for approximately $10.54 per share, which matches the recent market price, but there is no assurance the business combination will close even with the extension.

• · The Business Combination Agreement was entered into on October 13, 2025, and amended on December 22, 2025 and July 13, 2026.
• · The Extension Amendment Proposal requires approval as a special resolution; the Adjournment Proposal as an ordinary resolution.
• · Redemption requests must be submitted by 5:00 p.m. Eastern Time on August 10, 2026 (two business days before the meeting).
• · If the extension is not approved and no business combination closes by August 14, 2026, the company will redeem 100% of Public Shares and liquidate; rights will expire worthless.
• · Insiders (Sponsors, officers, directors) may purchase Public Shares from redeeming investors at up to the redemption price, but have no current commitments to do so.

20-07-2026

Worksport Ltd (WKSP) filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Shareholders, scheduled for September 3, 2026. Key proposals include the election of five directors, ratification of Lumsden & McCormick, LLP as auditors, an advisory vote on special dividends from asset sales, and authorization for the Board to effect reverse stock splits (up to 1-for-250) or forward stock splits. CEO Steven Rossi beneficially owns 100% of the Series A Preferred Stock, which carries 51% of total voting power, giving him effective control over all proposals.

• · The Annual Meeting will be held in person on September 3, 2026 at 9:00 a.m. ET at the company's headquarters in West Seneca, New York.
• · Record Date for voting is July 7, 2026.
• · Quorum requires at least one-third of the votes entitled to be cast.
• · Proposal 4 authorizes reverse stock splits at a ratio between 1-for-2 and 1-for-250, or forward stock splits, with the exact ratio and timing determined by the Board, valid until the second anniversary of the meeting.
• · CEO Steven Rossi controls 51% of total voting power through his ownership of all Series A Preferred Stock, ensuring passage of any proposal he supports.
• · The proxy statement was made available online via www.proxypush.com/WKSP starting July 23, 2026.

20-07-2026

VSee Health, Inc. filed its definitive proxy statement (DEF 14A) on July 20, 2026, detailing board composition, committee assignments, and corporate governance policies. The board held 11 meetings in fiscal 2025 with over 75% attendance by each member. The filing also discloses related-party transactions, including a $2,000,000 secured note issued to an affiliate of a bridge investor on December 31, 2024, and several loan conversions into common stock totaling $1,785,000 from 2023-2024. No executive compensation or option grants are discussed, and the company has adopted insider trading and clawback policies.

• · All five non-employee directors (Lowdermilk, O'Sullivan, Metzger, Fairfax, Wickersham) are deemed independent under Nasdaq rules and Rule 10A-3.
• · Kevin Lowdermilk qualifies as an audit committee financial expert under SEC rules.
• · The company has no formal policy on director attendance at annual stockholder meetings but strongly encourages it.
• · No executive officer serves on the board or compensation committee of any entity with an executive officer on VSee's board (no interlocks).
• · The company has not granted stock options to its named executive officers (NEOs) and has no policy or practice regarding option grant timing.
• · Stockholder communications must be in writing, signed, and include specific disclosures for proposals or director nominations (e.g., share class, holdings, agreements).
• · The clawback policy applies to incentive compensation in the event of an accounting restatement or significant misconduct causing financial/reputational harm.

20-07-2026

Intrusion Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held virtually on August 27, 2026. Key proposals include the election of five directors, ratification of Whitley Penn LLP as auditors, and approval of the potential issuance of shares exceeding the Nasdaq 19.9% threshold in connection with the Membership Interest Purchase Agreement dated June 29, 2026, to acquire OW Cyber LLC from VigilAigent Corp. The company had 22,757,075 shares of common stock outstanding as of the June 30, 2026 record date.

• · The annual meeting will be held virtually at www.virtualshareholdermeeting.com/INTZ2026.
• · Proposal 3 requires approval of the potential issuance of shares exceeding the Nasdaq 19.9% threshold; 2,223,549 shares issued to Seller in the First Closing are excluded from voting on this proposal.
• · The record date for voting is June 30, 2026.
• · Proposal 4 seeks approval to adjourn the meeting if necessary to solicit additional proxies for Proposal 3.

20-07-2026

Sound Shore Fund, Inc. is soliciting shareholder approval for a reorganization into a newly created series of Forum Funds II, a Delaware statutory trust, to gain operational, cost, and compliance efficiencies. The reorganization is expected to be tax-free, with no changes to investment objectives, strategies, risks, portfolio managers, or advisory fees. The Board unanimously recommends a vote 'FOR' the proposal, and the special meeting is scheduled for September 11, 2026.

• · The special meeting will be held on September 11, 2026 at 10:00 a.m. Eastern Time at 190 Middle Street, Portland, Maine.
• · Shareholders of record as of July 10, 2026 are entitled to vote.
• · The reorganization is expected to take effect on or about September 30, 2026.
• · Proxy materials will be mailed beginning on or about July 27, 2026.
• · Shareholders can vote by mail, phone (855-305-0857), or online at www.OkapiVote.com/SoundShore.
• · The net expense ratio for the New Fund is expected to be the same as or lower than the current fund's expense ratio.

20-07-2026

Bow River Capital Evergreen Fund is seeking shareholder approval of new advisory and sub-advisory agreements following the planned acquisition of its existing adviser, Bow River Advisers LLC, by New York Life Investment Management Holdings LLC. The transaction will result in NYLIM becoming the investment adviser and Apogem Capital LLC serving as sub-adviser, while the current portfolio management team and investment strategy remain unchanged. The Board unanimously recommends a vote 'FOR' the proposals, and there will be no increase in the advisory fee rate.

• · The Special Meeting will be held on August 31, 2026 at 9:00 a.m. Mountain Time in Denver, Colorado.
• · Record date for shareholder voting is May 28, 2026.
• · Proxy materials are being mailed on or about July 27, 2026.
• · The transaction is expected to close on or about September 30, 2026.
• · If shareholders do not approve the new agreements before closing, interim agreements will allow NYLIM and Apogem to serve for up to 150 days, with fees held in an interest-bearing escrow account.
• · Apogem has 35 years of experience and its senior team averages more than 20 years of experience.
• · The Existing Adviser and Apogem have been working together since shareholders approved Apogem as an investment consultant in 2024.